Findings demonstrated the expected clinical benefits, with sustained improvements in lung function metrics consistent with previous clinical trial data. Adults with Burkholderia cepacia complex colonisation showed variable responses, with some experiencing sustained clinical benefits while others demonstrated persistent infection-related complications despite improved CFTR function. Perhaps most intriguingly, the study identified potential signals suggesting that microbial adaptation may persist despite clinical gains. The research team noted that while forced expiratory volume in one second (FEV₁) improvements remained durable across the observation period, certain pathogen-specific trends raised questions about long-term infection risk stratification. Future therapies will need to demonstrate not only functional improvements but also favourable long-term microbiological profiles.